Literature DB >> 12804128

Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: an open-label extension trial.

Brian McConville1, Lynn Carrero, Dennis Sweitzer, Larry Potter, Robert Chaney, Keith Foster, Michael Sorter, Loren Friedman, Kerri Browne.   

Abstract

Quetiapine is a novel, atypical antipsychotic agent that has been shown to provide long-term efficacy without serious adverse effects in adults. This is the first study of the extended use of quetiapine in adolescents. Five boys and 5 girls, ages 12.3 to 15.9 years, with diagnoses of schizoaffective disorder (n = 7) or bipolar disorder with psychotic features (n = 3) were eligible for entry into this single-site, 88-week, open-label trial. Subjects had completed a pharmacokinetic study over 23 days, during which the dosage of quetiapine was increased sequentially from 25 mg bid to a maximum of 400 mg bid (800 mg/day) (McConville et al. 2000). In the open-label extension of this trial, which followed directly after this trial, a physician's choice design allowed for flexible dose titration of quetiapine by the study physician to an optimal dose for each patient, with ending doses ranging from 300 mg/day to 800 mg/day. Concomitant medications, especially for anxiety and/or manic symptoms, were allowed as deemed necessary. Tolerability and safety were assessed using clinical laboratory tests, physical examinations, measurements of vital signs, interviews for selective symptomatology, and electrocardiograms. Psychiatric measurements included the 18-item Brief Psychiatric Rating Scale (BPRS), the Clinical Global Impression (CGI) scale, and the modified Scale for the Assessment of Negative Symptoms (SANS). Neurologic symptom ratings included the Simpson-Angus Scale and the Abnormal Involuntary Movement Scale. Mean BPRS, CGI, and SANS scores improved significantly during the trial (p < 0.05). No extrapyramidal symptoms or evidence of tardive dyskinesia was seen. Clinically, there was a nonsignificant increase in mean weight and body mass index at week 64. This long-term study suggests that quetiapine is a well-tolerated antipsychotic agent that is efficacious for the treatment of symptoms of selected psychotic disorders in adolescents.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12804128     DOI: 10.1089/104454603321666216

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   2.576


  16 in total

Review 1.  Management of schizophrenia in children and adolescents: focus on pharmacotherapy.

Authors:  Gabriele Masi; Francesca Liboni
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

2.  Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics.

Authors:  Scott W Grimm; Neil M Richtand; Helen R Winter; Karen R Stams; Stots B Reele
Journal:  Br J Clin Pharmacol       Date:  2006-01       Impact factor: 4.335

3.  Prevalence of movement disorders in adolescent patients with schizophrenia and in relationship to predominantly atypical antipsychotic treatment.

Authors:  Stefan Gebhardt; Fabian Härtling; Markus Hanke; Markus Mittendorf; Frank M Theisen; Karin Wolf-Ostermann; Phillip Grant; Matthias Martin; Christian Fleischhaker; Eberhard Schulz; Helmut Remschmidt
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-04-28       Impact factor: 4.785

Review 4.  Use of quetiapine in children and adolescents.

Authors:  Gabriele Masi; Annarita Milone; Stefania Veltri; Raffaella Iuliano; Chiara Pfanner; Simone Pisano
Journal:  Paediatr Drugs       Date:  2015-04       Impact factor: 3.022

Review 5.  Children with schizophrenia: clinical picture and pharmacological treatment.

Authors:  Gabriele Masi; Maria Mucci; Cinzia Pari
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

6.  Relations between movement disorders and psychopathology under predominantly atypical antipsychotic treatment in adolescent patients with schizophrenia.

Authors:  Stefan Gebhardt; Fabian Härtling; Markus Hanke; Frank M Theisen; Richard von Georgi; Phillip Grant; Markus Mittendorf; Matthias Martin; Christian Fleischhaker; Eberhard Schulz; Helmut Remschmidt
Journal:  Eur Child Adolesc Psychiatry       Date:  2007-09-14       Impact factor: 4.785

7.  Activating and Tranquilizing Effects of First-Time Treatment with Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Youth.

Authors:  Zainab Al-Dhaher; Sandeep Kapoor; Ema Saito; Scott Krakower; Lisa David; Theodore Ake; John M Kane; Christoph U Correll; Maren Carbon
Journal:  J Child Adolesc Psychopharmacol       Date:  2016-04-19       Impact factor: 2.576

Review 8.  Quetiapine. A review of its use in the management of schizophrenia.

Authors:  Susan M Cheer; Antona J Wagstaff
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 9.  Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical review.

Authors:  José María Martínez-Ortega; Silvia Funes-Godoy; Francisco Díaz-Atienza; Luis Gutiérrez-Rojas; Lucía Pérez-Costillas; Manuel Gurpegui
Journal:  Eur Child Adolesc Psychiatry       Date:  2013-03-17       Impact factor: 4.785

Review 10.  Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence, clinical relevance, and management.

Authors:  Kimberly A Stigler; Marc N Potenza; David J Posey; Christopher J McDougle
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.